- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Zenas BioPharma, Inc. GAAP EPS of -$5.02 | 2 | Seeking Alpha | ||
| Di | Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 99 | GlobeNewswire (Europe) | -INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma... ► Artikel lesen | |
| Di | Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 71 | GlobeNewswire (Europe) | -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-... ► Artikel lesen | |
| 07.11. | Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences | 204 | GlobeNewswire (Europe) | WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the... ► Artikel lesen | |
| 08.10. | Zenas started at buy by four banks on lead drug potential | 2 | Seeking Alpha | ||
| 08.10. | Morgan Stanley bullisch für Zenas Biopharma-Aktie aufgrund zunehmender Dynamik bei obexelimab-Studien | 8 | Investing.com Deutsch | ||
| 08.10. | Citi sieht Aufwärtspotenzial für Zenas Biopharma-Aktie aufgrund von Fortschritten bei Obexelimab in wichtigen Studien | 3 | Investing.com Deutsch | ||
| 08.10. | Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials | 3 | Investing.com | ||
| 08.10. | Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum | 4 | Investing.com | ||
| 08.10. | Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials | 1 | Investing.com | ||
| 08.10. | Jefferies zeigt sich bullisch für Zenas-Aktie aufgrund von Fortschritten bei Obexelimab in Autoimmun-Studien | 2 | Investing.com Deutsch | ||
| 08.10. | Guggenheim setzt auf Zenas-Aktie aufgrund vielversprechender Aussichten für Hauptmedikament Obexelimab | 2 | Investing.com Deutsch | ||
| 08.10. | Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab | 2 | Investing.com | ||
| 21.09. | Zenas BioPharma CEO acquires $360k worth of company shares | 1 | Investing.com | ||
| 19.09. | Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | 251 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen | |
| 18.09. | Zenas BioPharma director acquires $999k in company stock | 3 | Investing.com | ||
| 17.09. | IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx | 2 | The Armchair Trader | ||
| 17.09. | Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock | 1 | Investing.com | ||
| 17.09. | Zenas BioPharma director buys $7.48m in company stock | 1 | Investing.com | ||
| 17.09. | Zenas BioPharma director Jason Raleigh acquires $15 million in company stock | 4 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 286,20 | +0,25 % | Verlustreicher Tag für Amgen-Aktionäre: Aktienkurs sinkt deutlich (284,9269 €) | Keinen Grund zur Freude haben Aktionäre von Amgen : Der Kurs des Anteilsscheins sackt kräftig ab. Ein Abschlag auf zwischenzeitlich 302,41 US-Dollar beschert der Aktie von Amgen zur Stunde einen hinteren... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 765,20 | +0,45 % | DelveInsight Business Research, LLP: Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight | After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 62,60 | -0,79 % | Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) | ||
| ARROWHEAD PHARMACEUTICALS | 20,350 | -0,63 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome | Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 27,980 | -0,50 % | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the... ► Artikel lesen | |
| INSMED | 67,00 | 0,00 % | Insmed Incorporated: Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | BRIDGEWATER, N.J., Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first-... ► Artikel lesen | |
| SCHOLAR ROCK | 25,400 | -2,31 % | Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... ► Artikel lesen | |
| PROQR THERAPEUTICS | 3,842 | +1,80 % | ProQR Therapeutics N.V. - 6-K, Report of foreign issuer | ||
| THERATECHNOLOGIES | 1,080 | 0,00 % | Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance | MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 57,00 | +1,79 % | CRNX-Aktie erreicht Allzeithoch von 60,95 US-Dollar | ||
| KINIKSA PHARMACEUTICALS | 22,640 | -1,57 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $410 - $420 million -- Life... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 2,035 | -3,55 % | Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright | ||
| ENSYSCE BIOSCIENCES | 0,710 | 0,00 % | Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2024 Financial Results | Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPARSubmitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE... ► Artikel lesen | |
| QIAGEN | 40,205 | -2,20 % | DAX-Check LIVE: Daimler Truck, Delivery Hero, Heidelberg, Lanxess, Munich Re, Nordex, Qiagen & Co. | Nachdem gestern feststand, dass Donald Trump die US-Wahl für sich entschieden hat, stieg der DAX zunächst um rund 1,5 Prozent an. Doch dann trat schnell Ernüchterung ein. Am Ende gab der DAX 1,13 Prozent... ► Artikel lesen | |
| EVOTEC | 8,565 | +5,55 % | TUI, Evotec, BioNxt Solutions: SHORT SQUEEZE, KURSDEBAKEL und MOMENTUM AKTIE | 50 % hat die Aktie von BioNxt Solutions seit Ende August zulegen können. Die Chancen stehen gut, dass das Momentum bei dem Biotech-Unternehmen anhält. Denn allein um das Niveau von Januar zu erreichen... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 19,450 Euro und damit -5,63 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.
